G1 Therapeutics, Inc.

Anne Y Lai

Jay Copeland Strum

Patrick Joseph Roberts

Jessica A Sorrentino

The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.

Growing community of inventors

Cary, NC, United States of America

Anne Y Lai